Previous 10 | Next 10 |
Gainers: Atreca (NASDAQ:BCEL) +20%. Alignment Healthcare (NASDAQ:ALHC) +16%. Puma Biotechnology (NASDAQ:PBYI) +15%. Humanigen (NASDAQ:HGEN) +13%. agilon health (NYSE:AGL) +8%. Losers: DBV Technologies (NASDAQ:DBVT) -22%. Ocugen (NASDAQ:OCGN) -20%. ...
Clinical-stage biotech, Humanigen (NASDAQ:HGEN) has added ~6% in the pre-market after two of the senior officers of the company, including Chief Executive Cameron Durrant, disclosed insider purchases through SEC filings on Friday. On Mar. 02, Cameron has bought 40,000 company s...
Sweetgreen (NYSE:SG) +18% on Q4 results. Funko FNKO +18% on Q4 earnings beats, upside FY22 guidance FedNat Holding (NASDAQ:FNHC) +13% on Q4 results. Indonesia Energy (NYSE:INDO) +18%. The Gap (NYSE:GPS) +7% on Q4 results. Humanigen (NASDAQ:HGEN) +6%. ...
Humanigen press release (NASDAQ:HGEN): FY GAAP EPS of -$0.53 beats by $0.24. Revenue of $1.04M (+235.5% Y/Y) misses by $132.52M. As of December 31, 2021, the company had cash and cash equivalents of $70.0M. For further details see: Humanigen GAAP EPS of -$0.53 beats by $0.24, revenue of...
Humanigen, Inc. (Nasdaq: HGEN) (Humanigen), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called “cytokine storm” with its lead drug candidate, lenzilumab, today reported financial results for the year ended December...
Humanigen, Inc. (Nasdaq: HGEN), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,’ announced today that management will present and participate at several events in March with investors, analysts,...
Humanigen, Inc. (Nasdaq: HGEN), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,’ announced today that Timothy E. Morris, COO/CFO, will be presenting at the upcoming 2022 BIO CEO & Investor...
Humanigen, Inc. (Nasdaq: HGEN), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,’ announced today that lenzilumab is now available for certain hospitalized COVID-19 patients through its newly-lau...
Burlingame, Calif.-based Humanigen (NASDAQ:HGEN) is collaborating with Cenexi to make the French company a preferred supplier for its potential COVID-19 therapy lenzilumab in France and the EU. The companies will execute an agreement under which Cenexi will provide aseptic fill and finish ser...
Cenexi to Become Preferred Drug Product Supplier for France and the European Union Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine s...
News, Short Squeeze, Breakout and More Instantly...
Williams Industrial Services Group Inc. (WLMSQ) is expected to report $-0.15 for Q3 2023 Cellcom Israel Limited (CELJF) is expected to report for quarter end 2023-09-30 Central Japan Railway Co ADR (CJPRY) is expected to report for Q2 2024 CW Petroleum Corp (CWPE) is expected to repor...
Strategic Environmental & Energy Resources Inc (SENR) is expected to report for Q1 2024 Biocept Inc. (BIOCQ) is expected to report for Q1 2024 Kalera Public Limited Company (KALRQ) is expected to report for quarter end 2023-09-30 Lanvin Group Holdings Limited (LANV) is expected to...
Murata Manufacturing Co. Ltd. ADR (MRAAY) is expected to report $0.27 for Q2 2024 Quotient Limited (QTNTQ) is expected to report for quarter end 2023-09-30 Evaxion Biotech A/S (EVAX) is expected to report for Q3 2023 American Virtual Cloud Technologies Inc. (AVCTQ) is expected to repo...